Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors - Results from a systematic review and meta-analysis of randomized controlled trials

被引：147

作者：

Sahebkar, Amirhossein ^{[1
,2
]}

Serban, Corina ^{[3
]}

Ursoniu, Sorin ^{[4
]}

Wong, Nathan D. ^{[5
]}

Muntner, Paul ^{[6
]}

Graham, Ian M. ^{[7
]}

Mikhailidis, Dimitri P. ^{[8
]}

Rizzo, Manfredi ^{[9
]}

Rysz, Jacek ^{[10
]}

Sperling, Laurence S. ^{[11
,12
]}

Lip, Gregory Y. H. ^{[13
]}

Banach, Maciej ^{[14
]}

机构：

[1] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran

[2] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Metab Res Ctr, Perth, WA 6009, Australia

[3] Victor Babes Univ Med & Pharm, Discipline Pathophysiol, Dept Funct Sci, Timisoara, Romania

[4] Victor Babes Univ Med & Pharm, Discipline Publ Hlth, Dept Funct Sci, Timisoara, Romania

[5] Univ Calif Irvine, Div Cardiol, Heart Dis Prevent Program, Irvine, CA USA

[6] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA

[7] Univ Med Ctr Rotterdam, Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands

[8] UCL, Sch Med, Dept Clin Biochem, London W1N 8AA, England

[9] Univ Palermo, Biomed Dept Internal Med & Med Specialties, I-90133 Palermo, Italy

[10] Med Univ Lodz, Chair Nephrol & Hypertens, PL-90549 Lodz, Poland

[11] Emory Univ, Dept Med, Atlanta, GA 30322 USA

[12] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA

[13] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England

[14] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 189卷

关键词：

Resveratrol; C reactive protein; CRP; Antioxidants; Inflammation; ENDOTHELIAL FUNCTION; INSULIN SENSITIVITY; TRANS-RESVERATROL; ORAL RESVERATROL; CANCER-TREATMENT; FRENCH PARADOX; CLINICAL-TRIAL; BLOOD-PRESSURE; BIOAVAILABILITY; METABOLISM;

D O I：

10.1016/j.ijcard.2015.04.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. Methods: The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics. Results: Meta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: -0.144 mg/L, 95% CI: -0.968-0.680, p = 0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49 mg/dL, 95% CI: -14.96-17.93, p = 0.859), low density lipoprotein cholesterol (WMD: -0.31 mg/dL, 95% CI: -9.57-8.95, p = 0.948), triglycerides (WMD: 2.67 mg/dL, 95% CI: -28.34-33.67, p = 0.866), and glucose (WMD: 1.28 mg/dL, 95% CI: -5.28-7.84, p = 0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: -4.18 mg/dL, 95% CI: -6.54 to -1.82, p = 0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82 mm Hg, 95% CI: -8.86-10.50, p = 0.868) and diastolic blood pressure (WMD: 1.72 mm Hg, 95% CI: -6.29-9.73, p = 0.674). Conclusions: This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：47 / 55

页数：9

共 67 条

[51] Potential of resveratrol in the treatment of heart failure [J].